Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Stopped The tolerability to benefit ratio based on maximum weight loss observed was not considered favorable at the doses studied and the study was terminated early

Conditions

• Obesity

Interventions

• DRUG: MBL949
• DRUG: Placebo

Sponsor

Novartis Pharmaceuticals